Your session is about to expire
← Back to Search
DIAPI for Diabetes
N/A
Recruiting
Led By Jean-Marie Boutin, MD, PhD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights
Study Summary
This trial is designed to assess whether DIAPI is an effective and safe tool to simplify the complex task of peri-endoscopy management of diabetes mellitus, providing individualized instructions and guidelines to both patients and healthcare professionals.
Who is the study for?
This trial is for people who have had diabetes for at least 6 months, are on medication for it, and have an endoscopy scheduled in two weeks or more. It's designed to help manage their diabetes around the time of their procedure.Check my eligibility
What is being tested?
The study tests a web app called DIAPI against usual care. DIAPI gives personalized instructions on managing diabetes meds before and during endoscopy procedures. The goal is to see if DIAPI can match or outperform standard doctor advice.See study design
What are the potential side effects?
Since this trial involves management guidelines rather than new medications, direct side effects from interventions aren't expected. However, risks may include potential mismanagement of blood sugar levels.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Concordance rate of duplicate prescriptions generated by DIAPI when two different healthcare workers collect data for the same patient. (Part 1 of study)
proportion of patients with glycaemia level within target from arrival to departure from the endoscopy unit, i.e. between 4 - 10 mmol/L. (Part 2 of study)
Secondary outcome measures
Healthcare workers' satisfaction level with the use of DIAPI, assessed by a questionnaire. (Part 1 of study)
Proportion of DIAPI orders for which the endocrinologist disagrees with at least one of its recommendations. (Part 1 of study)
Proportion of participants for whom an endocrinology consultation was recommended by DIAPI. (Part 1 of study)
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: DIAPIExperimental Treatment1 Intervention
Patients will receive the care for their diabetes recommended by the DIAPI algorithm during their peri-procedural period.
Group II: Usual CareActive Control1 Intervention
Patients will receive usual care for their diabetes during their peri-procedural period.
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
366 Previous Clinical Trials
129,477 Total Patients Enrolled
1 Trials studying Diabetes
Jean-Marie Boutin, MD, PhDPrincipal InvestigatorUniversité de Montréal
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there open opportunities to join this trial currently?
"Clinicaltrials.gov states that this clinical trial is actively recruiting patients as of December 1st, 2023; the original posting was on September 1st, 2023."
Answered by AI
How many test subjects are involved in this research?
"Indeed, as indicated by clinicaltrials.gov, this medical investigation is actively searching for participants. This trial was initially shared on September 1st 2023 and has been recently updated on December 1st 2023. In total the trial requires 160 individuals across a single site to take part in the study."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger